問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1621Cases

2018-05-04 - 2020-12-31

Phase II

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia

  • Condition/Disease

    Patients with established Schizophrenia (as per DSM-5) who are clinically stable

  • Test Drug

    BI 425809

Participate Sites
4Sites

Terminated4Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2015-12-08 - 2018-08-30

Phase II

A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone

  • Condition/Disease

    castration-resistant prostate cancer, CRPC

  • Test Drug

    BI 836845

Participate Sites
4Sites

Terminated4Sites

2015-04-01 - 2018-12-31

Phase III

Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 or 150 mg, oral, b.i.d) versus acetylsalicytic acid (100mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).

  • Condition/Disease

    Embolic stroke of undetermined source

  • Test Drug

    Pradaxa/Placebo

Participate Sites
14Sites

Terminated13Sites

Study ended1Sites

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2014-08-08 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-06-01 - 2017-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-08-08 - 2017-10-31

Phase III

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

  • Condition/Disease

    plaque psoriasis

  • Test Drug

    BI655066

Participate Sites
5Sites

Terminated5Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2008-12-01 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2008-03-01 - 2010-06-30

Phase II/III

Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing erlotinib or gefitinib.

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    BIBW 2992

Participate Sites
7Sites

Terminated7Sites

2006-08-01 - 2009-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-09-01 - 2009-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 152 153 154 155 156 163
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB